Barrett & Company’s AbbVie ABBV Stock Holding History

Barrett & Company’s Portfolio ABBV Stock Details ABBV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$696K	Sell	2,659 -50	-2%	-$12.8K	0.19%	72
2026 Q2	$682K	Sell	2,709 -250	-8%	-$53.8K	0.19%	80
2026 Q1	$644K	Hold	2,959	–	–	0.22%	69
2025 Q4	$676K	Hold	2,959	–	–	0.23%	68
2025 Q3	$685K	Hold	2,959	–	–	0.23%	68
2025 Q2	$549K	Hold	2,959	–	–	0.21%	76
2025 Q1	$620K	Hold	2,959	–	–	0.27%	66
2024 Q4	$526K	Buy	2,959 +12	+0.4%	+$2.21K	0.22%	75
2024 Q3	$582K	Hold	2,947	–	–	0.25%	69
2024 Q2	$505K	Sell	2,947 -50	-2%	-$8.28K	0.23%	74
2024 Q1	$546K	Hold	2,997	–	–	0.26%	67
2023 Q4	$464K	Sell	2,997 -49	-2%	-$7.14K	0.25%	78
2023 Q3	$454K	Buy	3,046 +1	+0%	+$147	0.27%	73
2023 Q2	$410K	Buy	3,045 +651	+27%	+$95.5K	0.24%	82
2023 Q1	$382K	Buy	2,394 +1	+0%	+$153	0.24%	81
2022 Q4	$387K	Hold	2,393	–	–	0.26%	78
2022 Q3	$387K	Buy	+2,393	New	+$343K	0.26%	78

Other funds holding ABBV

Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.32T AUM 44.66% 1-Year Est. Return

Bank of New York Mellon New York $608B AUM 32.77% 1-Year Est. Return

UBS Group Zurich, Switzerland $765B AUM 28.39% 1-Year Est. Return

Amundi Paris, France $496B AUM 35.36% 1-Year Est. Return

Deutsche Bank Frankfurt Am Main Ge, Germany $362B AUM 34.89% 1-Year Est. Return

Fisher Asset Management Camas, Washington $348B AUM 26.9% 1-Year Est. Return

Nuveen Charlotte, North Carolina $420B AUM 34.97% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $551B AUM 33.95% 1-Year Est. Return

Boston Partners Boston, Massachusetts $111B AUM 30.48% 1-Year Est. Return

Barrett & Company's ABBV Position: Q3 2026 in Review

Barrett & Company reduced its AbbVie (ABBV) stake by 1.8% in Q3 2026, selling an estimated $12.8K and leaving 2,659 shares worth $696K. The position accounts for 0.19% of the portfolio, ranked #72.

Barrett & Company first reported a position in ABBV in Q3 2022 and has held it in 17 quarters since. 3,064 funds tracked by Wall St. Rank hold ABBV as of Q3 2026.

Barrett & Company held 2,659 shares of AbbVie worth $696K as of Q3 2026.
Barrett & Company sold 50 AbbVie shares in Q3 2026, an estimated $12.8K.
AbbVie made up 0.19% of Barrett & Company's portfolio in Q3 2026, its #72 holding.
Barrett & Company first reported a position in AbbVie in Q3 2022 and has held it in 17 quarters since.
3,064 funds tracked by Wall St. Rank held AbbVie as of Q3 2026.

Based on Barrett & Company's 13F filing for Q3 2026, filed 22 Oct 2026.